Gastric cancer, breast cancer
Conditions
Interventions
Pregabalin is administered 75mg bid and increased gradually 150mg bid over 1week.
Duloxetine is administered 40mg qd. To begin administering 20mg qd, duloxetine is increased 40mg qd after an interval
Sponsors
Osaka Medical College Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients who have diagnosed gastric or breast cancer by cytodiagnosis or histological diagnosis. 2) Patients who have chemotherapy -related neurotoxicity (Grade2:CTCAE v4.0) and pain. 3) ECOG PS of 0 or 1 4) Adequate function of vital organs 5) Satisfactory oral feeding 6) Written informed consent
Exclusion criteria
Exclusion criteria: 1) Serious drug allergy 2) Active double cancer 3) Active infection 4) Serious coexisting illness 5) History of pregabalin and duloxetine treatment 6) Severe renal dysfunction (Creatinine clearance <30mL/min) 7) Patients with using electronic implants or other cardiac pacemaker 8) Pregnant or lactating women or men who have desire father a child 9) Investigator's judgement
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients who was improved FACT-Taxane after administering pregabalin or duloxetine. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Adverse effect of pregabalin and duloxetine 2) Investigation of QOL (FACT-Taxane) 3)Current perception threshold(CPT) | — |
Countries
Japan
Contacts
Public ContactMasashiro Goto
Osaka Medical College Hospital Chemotherapy Center
Outcome results
None listed